Amneal EU Limited Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Amneal EU Limited Pharmaceutical Import Records from India — 5 Products, $1.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Amneal EU Limited — Pharmaceutical Importer Profile (2026) | 5 Products, $1.0M Trade | TransData Nexus

Amneal EU Limited

Pharmaceutical Importer · United States · Respiratory Focus · $1.0M Total Trade · DGFT Verified

Amneal EU Limited is a pharmaceutical importer based in United States with a total trade value of $1.0M across 5 products in 4 therapeutic categories. Based on 20 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Amneal EU Limited sources from 1 verified Indian supplier, with Amneal Pharmaceuticals Private Limited accounting for 100.0% of imports.

Amneal EU Limited — Import Portfolio & Supplier Network

Amneal EU Limited import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Amneal EU Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Amneal Pharmaceuticals Private Limited	$4.0M	100	100.0%

Amneal EU Limited sources from 1 verified Indian supplier across 60 distinct formulations. The sourcing is highly concentrated — Amneal Pharmaceuticals Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Amneal EU Limited Import?

Formulation	Value	Ships
Triamcinolone acetonide INJ.suspension	$438.3K	9
Ursodiol capsules USP 300 MG 100	$150.6K	4
Ezetimibe tablets, USP 10 MG 30	$150.0K	3
Methylprednisolone acetate	$150.0K	3
Atropine sulfate ophthalmicsolution	$145.0K	3
Chlorpromazine hydrochloridetablets	$132.9K	3
Atropine sulfate ophthalmicsolution	$132.6K	4
Prednisone tablets, USP 10 MG 500	$120.1K	3
Prednisone tablets, USP 10 MG 100	$115.7K	3
Triamcinolone acetonide	$100.0K	2
Fulvestrant injection,250 MG/5ML	$100.0K	2
Hydroxychloroquine sulfatetablets	$100.0K	2
Ofloxacin otic solution 0.3 ,10 ML	$100.0K	2
Ephedrine sulfate injection	$100.0K	2
Ursodiol capsules, USP 300 MG 100	$100.0K	2

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Prednisone	Respiratory	$550.0K	11	2.0%	7
2	Methylprednisolone	Corticosteroids	$150.0K	3	0.5%	15
3	Chloroquine	Antimalarial & Antiparasitic	$100.0K	2	0.1%	14
4	Ephedrine	Respiratory & OTC	$100.0K	2	0.4%	12
5	Hydroxychloroquine	Antimalarial & Antiparasitic	$100.0K	2	0.1%	10

Amneal EU Limited imports 5 pharmaceutical products across 4 categories into United States totaling $1.0M.

Amneal EU Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Amneal EU Limited is a pharmaceutical importer and buyer based in the United States, specializing in the acquisition of finished pharmaceutical formulations from India. The company operates as a subsidiary of Amneal Pharmaceuticals, Inc., a publicly traded generics and specialty pharmaceutical company headquartered in Bridgewater, New Jersey. Amneal Pharmaceuticals, Inc. is one of the largest manufacturers of generic drugs in the United States, with a diverse portfolio spanning over 290 high-quality pharmaceuticals.

Amneal EU Limited plays a pivotal role in Amneal Pharmaceuticals' distribution network by sourcing finished pharmaceutical products from Indian manufacturers. This strategic sourcing enables Amneal to offer a broad range of generic and specialty medicines to the U.S. market, thereby enhancing access to essential medications. The company's operations are integral to Amneal Pharmaceuticals' mission of making healthy possible through the development, manufacturing, and distribution of a diverse portfolio of pharmaceutical products.

2Distribution Network

Amneal EU Limited's distribution network is primarily focused on facilitating the importation of finished pharmaceutical formulations from India to the United States. While specific details regarding warehouse locations and logistics capabilities are not publicly disclosed, the company's operations are designed to ensure efficient and timely delivery of pharmaceutical products to meet the demands of the U.S. market. The strategic sourcing from India allows Amneal Pharmaceuticals to leverage cost-effective manufacturing while maintaining high-quality standards for its product offerings.

3Industry Role

In the United States pharmaceutical supply chain, Amneal EU Limited functions as a key importer and buyer of finished pharmaceutical formulations from India. By sourcing these products, the company supports Amneal Pharmaceuticals' role as a primary wholesaler and distributor of generic and specialty medicines. This position enables Amneal to provide a diverse range of affordable medications to various stakeholders, including retail pharmacies, hospitals, and government entities. Through its import activities, Amneal EU Limited contributes significantly to the accessibility and affordability of essential medicines in the U.S. market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Amneal EU Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Amneal EU Limited's sourcing strategy exhibits a high degree of concentration, with all 20 shipments from India originating from a single supplier: Amneal Pharmaceuticals Private Limited. This single-source dependency may present certain risks, such as supply chain disruptions due to manufacturing issues or regulatory challenges faced by the supplier. However, this concentrated sourcing approach could also be a strategic choice, allowing for streamlined operations, consistent product quality, and potentially more favorable pricing agreements. The stability of the relationship between Amneal EU Limited and Amneal Pharmaceuticals Private Limited is crucial for maintaining a reliable supply chain. The absence of alternative suppliers in the current sourcing profile suggests a need for contingency planning to mitigate potential risks associated with this concentration.

2Supply Chain Resilience

The resilience of Amneal EU Limited's Indian supply chain is closely tied to the operational stability and regulatory compliance of Amneal Pharmaceuticals Private Limited. Given that all imported products are sourced from this single supplier, any disruptions in their manufacturing processes or regulatory approvals could significantly impact Amneal EU Limited's ability to meet U.S. market demands. The lack of backup suppliers and limited formulation diversity in the current sourcing strategy further underscores the need for a more diversified supply chain to enhance resilience. Ensuring that Amneal Pharmaceuticals Private Limited adheres to stringent regulatory standards and maintains robust quality control measures is essential for mitigating potential supply chain vulnerabilities.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation, approval, and marketing of pharmaceutical products. The FDA enforces regulations outlined in the Federal Food, Drug, and Cosmetic Act, which governs the safety, efficacy, and quality of drugs entering the U.S. market. For imported pharmaceutical products, the FDA requires compliance with Current Good Manufacturing Practice (CGMP) regulations, as specified in Title 21 of the Code of Federal Regulations (CFR) Parts 210 and 211. These regulations ensure that drugs are produced in a consistent and controlled manner, meeting the necessary quality standards. The FDA also mandates that foreign manufacturers, such as Amneal Pharmaceuticals Private Limited in India, register their facilities and list their products with the agency to facilitate the importation process.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent. Importers must ensure that their foreign suppliers hold valid FDA registrations and that their manufacturing facilities comply with CGMP standards. The FDA recognizes various international GMP certifications, including those from the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications are essential for foreign manufacturers seeking to export pharmaceutical products to the U.S. market. Additionally, importers must obtain an FDA import license and ensure that all imported products are accompanied by appropriate documentation, including Certificates of Analysis and Certificates of Compliance, to verify their quality and regulatory compliance.

Amneal EU Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Amneal EU Limited's product strategy focuses on importing finished pharmaceutical formulations from India across various therapeutic categories, including respiratory, antimalarial and antiparasitic, and corticosteroids. The top five products imported—prednisone, methylprednisolone, chloroquine, ephedrine, and hydroxychloroquine—align with these therapeutic areas. The emphasis on respiratory medications (55.0% of imports) suggests a strategic focus on addressing prevalent respiratory conditions in the U.S. market. The inclusion of antimalarial and antiparasitic drugs (20.0%) and corticosteroids (15.0%) indicates a commitment to providing treatments for a diverse range of health conditions. This product mix reflects Amneal EU Limited's strategy to meet the varied medical needs of the U.S. population by sourcing a comprehensive portfolio of pharmaceutical products from India.

2Sourcing Profile

Amneal EU Limited's sourcing strategy is centered on importing generic pharmaceutical formulations from India, with a particular emphasis on finished dosage forms such as tablets, capsules, syrups, and injections. This approach leverages India's robust pharmaceutical manufacturing capabilities and cost advantages. By focusing on finished formulations, Amneal EU Limited can offer a diverse range of products without the complexities associated with raw material sourcing and manufacturing. India's compliance with international GMP standards, including EU GMP, WHO GMP, and PIC/S, further enhances the reliability and quality of the sourced products. This sourcing profile enables Amneal EU Limited to provide high-quality, affordable medications to the U.S. market, aligning with Amneal Pharmaceuticals' mission to make healthy possible.

Frequently Asked Questions — Amneal EU Limited

What products does Amneal EU Limited import from India?

Amneal EU Limited imports 5 pharmaceutical products across 4 categories. Top imports: Prednisone ($550.0K), Methylprednisolone ($150.0K), Chloroquine ($100.0K), Ephedrine ($100.0K), Hydroxychloroquine ($100.0K).

Who supplies pharmaceuticals to Amneal EU Limited from India?

Amneal EU Limited sources from 1 verified Indian suppliers. The primary supplier is Amneal Pharmaceuticals Private Limited (100.0% of imports, $4.0M).

What is Amneal EU Limited's total pharmaceutical import value?

Amneal EU Limited's total pharmaceutical import value from India is $1.0M, based on 20 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Amneal EU Limited focus on?

Amneal EU Limited imports across 4 categories. The largest: Respiratory (55.0%), Antimalarial & Antiparasitic (20.0%), Corticosteroids (15.0%).

Get Full Amneal EU Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

Amneal EU Limited

Amneal EU Limited — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Amneal EU Limited?

What Formulations Does Amneal EU Limited Import?

What Products Does Amneal EU Limited Import?

Top Products by Import Value

Amneal EU Limited Therapeutic Categories — 4 Specializations